Matthew Gubens, MD, MS, assistant clinical professor of thoracic oncology at the University of California, San Francisco, discussed the areas of lung immuno-oncology research where he anticipates significant advances will be made in coming years.
Matthew Gubens, MD, MS, assistant clinical professor of thoracic oncology at the University of California, San Francisco, discussed the areas of lung immuno-oncology (IO) research where he anticipates significant advances will be made in coming years.
Transcript (slightly modified)
Are you conducting any ongoing research on lung cancer immunotherapies?
Well, we’re certainly in the hunt of looking at these combination approaches. Certainly, I think one other exciting thing about this area has been the opportunity to work with immunologists who have been in the lab talking about this for years and finally engaging us clinically.
I think some of the interesting efforts we have are to do really sophisticated immuno-profiling. PDL-1 is a biomarker we have, I don’t think any of us think we’ll be using that exclusively 3 years from now. We’re really trying to be more savvy about blood-based biomarkers, proteomics, tumor mutation burden, and really having a sense for both patient selection but also patient follow-up. Do we have early signals of benefit, whether they’re blood-based, whether they’re biopsy-based, or even imaging-based?
I think some of the exciting work is also about PET tracers and may let us have an early sense of benefit, again with the idea of moving a patient off an ineffective treatment to move onto the next thing. So partly combinations, and really being savvy about biomarker development.
The other piece I’m really excited about is looking at a whole other area, looking at folks who have early-stage disease. We know that we’re finding more early-stage disease now that we do more lung cancer screening in at-risk populations, but the idea of maybe using PD-1 inhibition or other IO/IO combinations either neoadjuvantly, which also by the way gives us really nice tissue to work with, or adjuvantly, to see if we can improve cure rates, which is really of course all of our goals in lung cancer.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More